Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Shareholders??? Equity

v3.23.1
Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands
Total
Common Shares
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020   24,883,024    
Beginning balance at Dec. 31, 2020 $ 95,250 $ 0 $ 164,264 $ (69,014)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Founders earnout shares vested (in shares)   570,212    
Issuance of common shares upon vesting of RSUs (in shares)   268,895    
Exercise of warrants (in shares)   122,639    
Exercise of warrants $ 1,410   1,410  
Stock option exercise (in shares) 40,942 40,942    
Stock option exercise $ 10   10  
Share-based compensation expense 11,451   11,451  
Beneficial conversion feature of Convertible Note 4,748   4,748  
Conversions of Convertible Note to common shares (in shares)   720,085    
Conversions of Convertible Note to common shares 6,047   6,047  
Reclassification and other (420)   (420)  
Net Loss $ (45,726)     (45,726)
Ending balance (in shares) at Dec. 31, 2021 26,605,797 26,605,797    
Ending balance at Dec. 31, 2021 $ 72,770 $ 0 187,510 (114,740)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common shares upon vesting of RSUs (in shares)   377,527    
Issuance of common stock, gross (in shares)   14,994,765    
Issuance of common shares, gross $ 27,686   27,686  
Stock option exercise (in shares) 158,882 151,694    
Stock option exercise $ 22   22  
Share-based compensation expense 2,343   2,343  
Equity issuance costs (1,361)   (1,361)  
Beneficial conversion feature of Convertible Note 1,750   1,750  
Conversions of Convertible Note to common shares (in shares)   1,507,000    
Conversions of Convertible Note to common shares 3,363   3,363  
Net Loss $ (66,165)     (66,165)
Ending balance (in shares) at Dec. 31, 2022 43,636,783 43,636,783    
Ending balance at Dec. 31, 2022 $ 40,408 $ 0 $ 221,313 $ (180,905)